Novonesis A/S

LSE:0Q4U Stock Report

Market Cap: DKK 199.1b

Novonesis Valuation

Is 0Q4U undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0Q4U when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 453.90
Fair Value
5.4% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: 0Q4U (DKK429.2) is trading below our estimate of fair value (DKK453.9)

Significantly Below Fair Value: 0Q4U is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0Q4U?

Key metric: As 0Q4U is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0Q4U. This is calculated by dividing 0Q4U's market cap by their current earnings.
What is 0Q4U's PE Ratio?
PE Ratio87.2x
Earnings€305.80m
Market Cap€26.68b

Price to Earnings Ratio vs Peers

How does 0Q4U's PE Ratio compare to its peers?

The above table shows the PE ratio for 0Q4U vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
CRDA Croda International
26.8x14.4%UK£4.2b
JMAT Johnson Matthey
4.1x-28.0%UK£2.2b
VCT Victrex
42.8x29.7%UK£736.7m
ANTO Antofagasta
27.3x18.9%UK£16.9b
0Q4U Novonesis
87.2x26.4%DKK 199.1b

Price-To-Earnings vs Peers: 0Q4U is expensive based on its Price-To-Earnings Ratio (87.2x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does 0Q4U's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0Q4U 87.2xIndustry Avg. 16.8xNo. of Companies13PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0Q4U is expensive based on its Price-To-Earnings Ratio (87.2x) compared to the European Chemicals industry average (16.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0Q4U's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0Q4U PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio87.2x
Fair PE Ratio28.6x

Price-To-Earnings vs Fair Ratio: 0Q4U is expensive based on its Price-To-Earnings Ratio (87.2x) compared to the estimated Fair Price-To-Earnings Ratio (28.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0Q4U forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 429.20
DKK 484.93
+13.0%
11.7%DKK 576.00DKK 388.00n/a16
Apr ’26DKK 404.50
DKK 491.31
+21.5%
11.8%DKK 598.00DKK 388.00n/a16
Mar ’26DKK 434.40
DKK 489.12
+12.6%
11.3%DKK 598.00DKK 388.00n/a16
Feb ’26DKK 412.31
DKK 486.24
+17.9%
11.8%DKK 598.00DKK 372.00n/a16
Jan ’26DKK 407.70
DKK 485.12
+19.0%
12.0%DKK 598.00DKK 364.00n/a16
Dec ’25DKK 413.70
DKK 484.05
+17.0%
11.7%DKK 586.00DKK 364.00n/a16
Nov ’25DKK 431.00
DKK 488.00
+13.2%
11.1%DKK 560.00DKK 360.00n/a15
Oct ’25DKK 482.79
DKK 487.50
+1.0%
11.0%DKK 560.00DKK 360.00n/a16
Sep ’25DKK 466.31
DKK 464.99
-0.3%
11.1%DKK 540.00DKK 360.00n/a16
Aug ’25DKK 440.76
DKK 458.43
+4.0%
10.6%DKK 540.00DKK 360.00n/a16
Jul ’25DKK 424.24
DKK 449.81
+6.0%
10.7%DKK 540.00DKK 350.00n/a16
Jun ’25DKK 408.60
DKK 437.35
+7.0%
9.1%DKK 500.00DKK 350.00n/a14
May ’25DKK 385.87
DKK 430.86
+11.7%
9.2%DKK 500.00DKK 350.00DKK 428.8614
Apr ’25DKK 405.13
DKK 419.78
+3.6%
9.6%DKK 500.00DKK 340.00DKK 404.5014
Mar ’25DKK 388.97
DKK 408.29
+5.0%
8.5%DKK 460.00DKK 326.00DKK 434.4014
Feb ’25DKK 361.99
DKK 397.38
+9.8%
8.2%DKK 450.00DKK 326.00DKK 412.3113
Jan ’25DKK 371.20
DKK 386.62
+4.2%
8.1%DKK 430.00DKK 326.00DKK 407.7013
Dec ’24DKK 355.52
DKK 376.54
+5.9%
9.0%DKK 430.00DKK 326.00DKK 413.7013
Nov ’24DKK 313.85
DKK 361.77
+15.3%
11.9%DKK 430.00DKK 275.00DKK 431.0013
Oct ’24DKK 285.79
DKK 374.00
+30.9%
12.6%DKK 460.00DKK 275.00DKK 482.7913
Sep ’24DKK 297.03
DKK 373.36
+25.7%
11.4%DKK 460.00DKK 300.00DKK 466.3114
Aug ’24DKK 335.95
DKK 385.64
+14.8%
11.3%DKK 460.00DKK 300.00DKK 440.7614
Jul ’24DKK 317.90
DKK 393.50
+23.8%
13.4%DKK 520.00DKK 300.00DKK 424.2414
Jun ’24DKK 337.83
DKK 396.36
+17.3%
12.6%DKK 520.00DKK 320.00DKK 408.6014
May ’24DKK 351.92
DKK 395.64
+12.4%
12.2%DKK 510.00DKK 320.00DKK 385.8714
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
DKK 487.08
Fair Value
11.9% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 00:27
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novonesis A/S is covered by 38 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Vitfell-RasmussenABG Sundal Collier
Carla BänzigerBank Vontobel AG
Sebastian SatzBarclays